Imvax Inc. Raises $112 Million in Series C Financing

Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme,  Phase 1 research into additional solid tumor indications and build out of the operational capabilities

PHILADELPHIA, JULY 16, 2020 – Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being studied in patients with glioblastoma multiforme (GBM), and whose proprietary technology has the potential to advance care for patients with serious, unmet medical needs in other solid tumor cancers, today announced the completion of a $112 million Series C financing. The round was led by existing investor HP WILD Holding  AG, with significant participation from other major shareholders – Ziff Capital Partners, Magnetar Capital, and TLP Investment Partners. This round also includes participation from a new institutional investor – Invus.


Canan Schuman, PharmD/PhD
Author: Canan Schuman, PharmD/PhD

Canan Schumann is Chief Editor for Axxiem and for Axxiem's blog "BiotechOntheWeb". When not writing for Axxiem, Canan works as a Clinical Research Scientist II at the Research and Development Department at Molecular Testing Labs, developing endpoint assays for the detection of infectious disease and cancer. Canan currently resides in Portland, Oregon, where he received his Honors Bachelor of Science (HBS), Doctor of Pharmacy (PharmD.), and his Doctor of Philosophy (Ph.D.) in Biopharmaceutics at Oregon State University.